ADIPOQ and Abdominal obesity: For adiponectin, participants in the highest tertile had significantly lower odds of obesity (OR 0.47, 95% CI 0.24–0.93) and abdominal obesity (OR 0.48, 95% CI 0.25–0.90) compared to the lowest tertile in Model 3.